Propella Therapeutics, Inc. presented a webinar titled “Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target” on February 9, 2021.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-02-20 00:37:592022-09-12 12:39:53Presentation (Webinar, February 9, 2021): Capsaicin - The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target
Propella Therapeutics, Inc. presented the results of its completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 13th Annual Pain Therapeutics Summit in Washington, DC on September 23, 2019.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-14 15:57:112021-09-09 15:20:20Capsaicin cream 0.025% as Monotherapy for Osteoarthritis: A double-blind study
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-14 15:54:092021-09-09 15:20:26Treatment of Arthritis with Topical Capsaicin: A Double-Blind Trial
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-14 15:50:552021-09-09 15:20:32Physician/Site Staff Assessments Contribute to High Placebo Response in Rheumatoid Arthritis Clinical Trials
Presentation (Webinar, February 9, 2021): Capsaicin – The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target
/in presentations /by georgePropella Therapeutics, Inc. presented a webinar titled “Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target” on February 9, 2021.
Presentation at the 13th Annual Pain Therapeutics Summit (September 23, 2019; Washington, DC): A phase 2 double-blind clinical trial (VZU00025) to examine the tolerability, safety and effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on osteoarthritis knee pain (OAKP)
/in presentations /by georgePropella Therapeutics, Inc. presented the results of its completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 13th Annual Pain Therapeutics Summit in Washington, DC on September 23, 2019.
Capsaicin cream 0.025% as Monotherapy for Osteoarthritis: A double-blind study
/in references (CGS-200-5) /by georgeTreatment of Arthritis with Topical Capsaicin: A Double-Blind Trial
/in references (CGS-200-5) /by georgePhysician/Site Staff Assessments Contribute to High Placebo Response in Rheumatoid Arthritis Clinical Trials
/in references (CGS-200-5) /by georgeDo cultures influence placebo response?
/in references (CGS-200-5) /by george